{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:07:01Z","timestamp":1791184021914,"version":"4.1.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1038\/ncpendmet0505","type":"journal-article","created":{"date-parts":[[2007,5,21]],"date-time":"2007-05-21T18:14:55Z","timestamp":1179771295000},"page":"458-469","source":"Crossref","is-referenced-by-count":84,"title":["Nonalcoholic fatty liver disease: from pathogenesis to patient care"],"prefix":"10.1038","volume":"3","author":[{"given":"Gabriel","family":"Perlemuter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Bigorgne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Cassard-Doulcier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Naveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFncpendmet0505_CR1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","volume":"55","author":"J Ludwig","year":"1980","unstructured":"Ludwig J et al. (1980) Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55: 434\u2013438","journal-title":"Mayo Clin Proc"},{"key":"BFncpendmet0505_CR2","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMra011775","volume":"346","author":"P Angulo","year":"2002","unstructured":"Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346: 1221\u20131231","journal-title":"N Engl J Med"},{"key":"BFncpendmet0505_CR3","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1053\/jhep.2002.32483","volume":"35","author":"ZM Younossi","year":"2002","unstructured":"Younossi ZM et al. (2002) Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 35: 746\u2013752","journal-title":"Hepatology"},{"key":"BFncpendmet0505_CR4","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1053\/gast.2002.33573","volume":"122","author":"JM Clark","year":"2002","unstructured":"Clark JM et al. (2002) Nonalcoholic fatty liver disease. Gastroenterology 122: 1649\u20131657","journal-title":"Gastroenterology"},{"key":"BFncpendmet0505_CR5","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/hep.1840200611","volume":"20","author":"S Bellentani","year":"1994","unstructured":"Bellentani S et al. (1994) Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology 20: 1442\u20131449","journal-title":"Hepatology"},{"key":"BFncpendmet0505_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/hep.20734","volume":"42","author":"G Bedogni","year":"2005","unstructured":"Bedogni G et al. (2005) Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42: 44\u201352","journal-title":"Hepatology"},{"key":"BFncpendmet0505_CR7","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1053\/jhep.2000.17894","volume":"32","author":"A Poonawala","year":"2000","unstructured":"Poonawala A et al. (2000) Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case\u2013control study. Hepatology 32: 689\u2013692","journal-title":"Hepatology"},{"key":"BFncpendmet0505_CR8","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/hep.510290347","volume":"29","author":"SH Caldwell","year":"1999","unstructured":"Caldwell SH et al. (1999) Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29: 664\u2013669","journal-title":"Hepatology"},{"key":"BFncpendmet0505_CR9","unstructured":"International Diabetes Federation: the IDF consensus worldwide definition of the metabolic syndrome [ http:\/\/www.idf.org\/webdata\/docs\/Metabolic_syndrome_definition.pdf ] (accessed 29 March 2007)"},{"key":"BFncpendmet0505_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1053\/gast.2001.25540","volume":"121","author":"JB Dixon","year":"2001","unstructured":"Dixon JB et al. (2001) Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121: 91\u2013100","journal-title":"Gastroenterology"},{"key":"BFncpendmet0505_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/qjmed\/92.2.73","volume":"92","author":"H Knobler","year":"1999","unstructured":"Knobler H et al. (1999) Fatty liver\u2014an additional and treatable feature of the insulin resistance syndrome. QJM 92: 73\u201379","journal-title":"QJM"},{"key":"BFncpendmet0505_CR12","doi-asserted-by":"publisher","first-page":"722","DOI":"10.7326\/0003-4819-143-10-200511150-00009","volume":"143","author":"M Hamaguchi","year":"2005","unstructured":"Hamaguchi M et al. (2005) The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143: 722\u2013728","journal-title":"Ann Intern Med"},{"key":"BFncpendmet0505_CR13","first-page":"23","volume-title":"Fatty Liver Disease. NASH and Related Disorders","author":"AJ McCullough","year":"2005","unstructured":"McCullough AJ (2005) The epidemiology and risk factors of NASH. In Fatty Liver Disease. NASH and Related Disorders, 23\u201337 (Eds Farrell G et al.) Malden: Blackwell Publishing"},{"key":"BFncpendmet0505_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mito.2005.10.004","volume":"6","author":"K Begriche","year":"2006","unstructured":"Begriche K et al. (2006) Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 6: 1\u201328","journal-title":"Mitochondrion"},{"key":"BFncpendmet0505_CR15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/ncpgasthep0186","volume":"2","author":"A Schaffler","year":"2005","unstructured":"Schaffler A et al. (2005) Mechanisms of disease: adipocytokines and visceral adipose tissue\u2014emerging role in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2: 273\u2013280","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"BFncpendmet0505_CR16","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1053\/j.gastro.2006.05.054","volume":"131","author":"H Tilg","year":"2006","unstructured":"Tilg H and Hotamisligil GS (2006) Nonalcoholic fatty liver disease: cytokine\u2013adipokine interplay and regulation of insulin resistance. Gastroenterology 131: 934\u2013945","journal-title":"Gastroenterology"},{"key":"BFncpendmet0505_CR17","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.1210\/jc.2004-2240","volume":"90","author":"E Bugianesi","year":"2005","unstructured":"Bugianesi E et al. (2005) Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 90: 3498\u20133504","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0505_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1172\/JCI200317797","volume":"112","author":"A Xu","year":"2003","unstructured":"Xu A et al. (2003) The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112: 91\u2013100","journal-title":"J Clin Invest"},{"key":"BFncpendmet0505_CR19","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1172\/JCI29126","volume":"116","author":"T Kadowaki","year":"2006","unstructured":"Kadowaki T et al. (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116: 1784\u20131792","journal-title":"J Clin Invest"},{"key":"BFncpendmet0505_CR20","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1073\/pnas.040561297","volume":"97","author":"R Faggioni","year":"2000","unstructured":"Faggioni R et al. (2000) Leptin-deficient (ob\/ob) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor \u03b1 and IL-18. Proc Natl Acad Sci USA 97: 2367\u20132372","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncpendmet0505_CR21","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1189\/jlb.68.4.437","volume":"68","author":"G Fantuzzi","year":"2000","unstructured":"Fantuzzi G and Faggioni R (2000) Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol 68: 437\u2013446","journal-title":"J Leukoc Biol"},{"key":"BFncpendmet0505_CR22","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1053\/gast.2002.33369","volume":"122","author":"F Marra","year":"2002","unstructured":"Marra F (2002) Leptin and liver fibrosis: a matter of fat. Gastroenterology 122: 1529\u20131532","journal-title":"Gastroenterology"},{"key":"BFncpendmet0505_CR23","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1073\/pnas.0409530102","volume":"102","author":"JM Montez","year":"2005","unstructured":"Montez JM et al. (2005) Acute leptin deficiency, leptin resistance, and the physiologic response to leptin withdrawal. Proc Natl Acad Sci USA 102: 2537\u20132542","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncpendmet0505_CR24","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1371\/journal.pmed.0010045","volume":"1","author":"M Lehrke","year":"2004","unstructured":"Lehrke M et al. (2004) An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 1: e45","journal-title":"PLoS Med"},{"key":"BFncpendmet0505_CR25","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1210\/jc.2005-1056","volume":"91","author":"C Pagano","year":"2006","unstructured":"Pagano C et al. (2006) Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab 91: 1081\u20131086","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0505_CR26","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1126\/science.1097243","volume":"307","author":"A Fukuhara","year":"2005","unstructured":"Fukuhara A et al. (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307: 426\u2013430","journal-title":"Science"},{"key":"BFncpendmet0505_CR27","doi-asserted-by":"publisher","first-page":"10610","DOI":"10.1073\/pnas.0504703102","volume":"102","author":"K Hida","year":"2005","unstructured":"Hida K et al. (2005) Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 102: 10610\u201310615","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncpendmet0505_CR28","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.crvi.2005.12.012","volume":"329","author":"G Ailhaud","year":"2006","unstructured":"Ailhaud G (2006) Adipose tissue as a secretory organ: from adipogenesis to the metabolic syndrome. C R Biol 329: 570\u2013577","journal-title":"C R Biol"},{"key":"BFncpendmet0505_CR29","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jaci.2005.02.023","volume":"115","author":"G Fantuzzi","year":"2005","unstructured":"Fantuzzi G (2005) Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 115: 911\u2013919","journal-title":"J Allergy Clin Immunol"},{"key":"BFncpendmet0505_CR30","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1073\/pnas.91.11.4854","volume":"91","author":"GS Hotamisligil","year":"1994","unstructured":"Hotamisligil GS et al. (1994) Tumor necrosis factor \u03b1 inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 91: 4854\u20134858","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncpendmet0505_CR31","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2337\/diab.45.7.881","volume":"45","author":"F Ofei","year":"1996","unstructured":"Ofei F et al. (1996) Effects of an engineered human anti-TNF-\u03b1 antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45: 881\u2013885","journal-title":"Diabetes"},{"key":"BFncpendmet0505_CR32","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1172\/JCI26498","volume":"116","author":"H Kanda","year":"2006","unstructured":"Kanda H et al. (2006) MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116: 1494\u20131505","journal-title":"J Clin Invest"},{"key":"BFncpendmet0505_CR33","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/hep.1840380426","volume":"38","author":"M Perez-Carreras","year":"2003","unstructured":"Perez-Carreras M et al. (2003) Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 38: 999\u20131007","journal-title":"Hepatology"},{"key":"BFncpendmet0505_CR34","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1172\/JCI200422422","volume":"114","author":"JD Browning","year":"2004","unstructured":"Browning JD and Horton JD (2004) Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114: 147\u2013152","journal-title":"J Clin Invest"},{"key":"BFncpendmet0505_CR35","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0891-5849(91)90192-6","volume":"11","author":"H Esterbauer","year":"1991","unstructured":"Esterbauer H et al. (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11: 81\u2013128","journal-title":"Free Radic Biol Med"},{"key":"BFncpendmet0505_CR36","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1053\/jhep.2001.28457","volume":"34","author":"DM Bissell","year":"2001","unstructured":"Bissell DM et al. (2001) Transforming growth factor \u03b2 and the liver. Hepatology 34: 859\u2013867","journal-title":"Hepatology"},{"key":"BFncpendmet0505_CR37","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/hep.20320","volume":"40","author":"Z Li","year":"2004","unstructured":"Li Z et al. (2004) Norepinephrine regulates hepatic innate immune system in leptin-deficient mice with nonalcoholic steatohepatitis. Hepatology 40: 434\u2013441","journal-title":"Hepatology"},{"key":"BFncpendmet0505_CR38","doi-asserted-by":"publisher","first-page":"G518","DOI":"10.1152\/ajpgi.00024.2006","volume":"292","author":"P Brun","year":"2007","unstructured":"Brun P et al. (2007) Increased intestinal permeability in obese mice: new evidences in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 292: G518\u2013G525","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"BFncpendmet0505_CR39","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1053\/gast.2000.19267","volume":"119","author":"K Cope","year":"2000","unstructured":"Cope K et al. (2000) Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology 119: 1340\u20131347","journal-title":"Gastroenterology"},{"key":"BFncpendmet0505_CR40","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/0016-5085(88)90183-7","volume":"95","author":"AM Diehl","year":"1988","unstructured":"Diehl AM et al. (1988) Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 95: 1056\u20131062","journal-title":"Gastroenterology"},{"key":"BFncpendmet0505_CR41","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1002\/hep.510300604","volume":"30","author":"P Angulo","year":"1999","unstructured":"Angulo P et al. (1999) Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30: 1356\u20131362","journal-title":"Hepatology"},{"key":"BFncpendmet0505_CR42","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1053\/jhep.2003.50229","volume":"37","author":"P Mofrad","year":"2003","unstructured":"Mofrad P et al. (2003) Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37: 1286\u20131292","journal-title":"Hepatology"},{"key":"BFncpendmet0505_CR43","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0168-8278(99)80032-4","volume":"31","author":"HL Bonkovsky","year":"1999","unstructured":"Bonkovsky HL et al. (1999) Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 31: 421\u2013429","journal-title":"J Hepatol"},{"key":"BFncpendmet0505_CR44","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1053\/jhep.2002.33892","volume":"36","author":"S Chitturi","year":"2002","unstructured":"Chitturi S et al. (2002) HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 36: 142\u2013149","journal-title":"Hepatology"},{"key":"BFncpendmet0505_CR45","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1053\/gast.2002.35354","volume":"123","author":"S Saadeh","year":"2002","unstructured":"Saadeh S et al. (2002) The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123: 745\u2013750","journal-title":"Gastroenterology"},{"key":"BFncpendmet0505_CR46","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/00004836-200508000-00012","volume":"39","author":"M Fishbein","year":"2005","unstructured":"Fishbein M et al. (2005) Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound. J Clin Gastroenterol 39: 619\u2013625","journal-title":"J Clin Gastroenterol"},{"key":"BFncpendmet0505_CR47","doi-asserted-by":"publisher","first-page":"E462","DOI":"10.1152\/ajpendo.00064.2004","volume":"288","author":"LS Szczepaniak","year":"2005","unstructured":"Szczepaniak LS et al. (2005) Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288: E462\u2013E468","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"BFncpendmet0505_CR48","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313\u20131321","journal-title":"Hepatology"},{"key":"BFncpendmet0505_CR49","first-page":"3","volume":"24","author":"EM Brunt","year":"2004","unstructured":"Brunt EM (2004) Nonalcoholic steatohepatitis. Semin Liver Dis 24: 3\u201320","journal-title":"Semin Liver Dis"},{"key":"BFncpendmet0505_CR50","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1053\/gast.2002.34168","volume":"123","author":"E Bugianesi","year":"2002","unstructured":"Bugianesi E et al. (2002) Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123: 134\u2013140","journal-title":"Gastroenterology"},{"key":"BFncpendmet0505_CR51","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S1542-3565(04)00014-X","volume":"2","author":"ZM Younossi","year":"2004","unstructured":"Younossi ZM et al. (2004) Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2: 262\u2013265","journal-title":"Clin Gastroenterol Hepatol"},{"key":"BFncpendmet0505_CR52","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/S0016-5085(00)70364-7","volume":"118","author":"V Ratziu","year":"2000","unstructured":"Ratziu V et al. (2000) Liver fibrosis in overweight patients. Gastroenterology 118: 1117\u20131123","journal-title":"Gastroenterology"},{"key":"BFncpendmet0505_CR53","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-230X-6-6","volume":"6","author":"V Ratziu","year":"2006","unstructured":"Ratziu V et al. (2006) Diagnostic value of biochemical markers (FibroTest\u2013FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 6: 6","journal-title":"BMC Gastroenterol"},{"key":"BFncpendmet0505_CR54","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.cld.2005.08.002","volume":"9","author":"TB Kelleher","year":"2005","unstructured":"Kelleher TB and Afdhal N (2005) Noninvasive assessment of liver fibrosis. Clin Liver Dis 9: 667\u2013683","journal-title":"Clin Liver Dis"},{"key":"BFncpendmet0505_CR55","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/00042737-200604000-00015","volume":"18","author":"J Foucher","year":"2006","unstructured":"Foucher J et al. (2006) Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2,114 examinations. Eur J Gastroenterol Hepatol 18: 411\u2013412","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"BFncpendmet0505_CR56","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","volume":"129","author":"LA Adams","year":"2005","unstructured":"Adams LA et al. (2005) The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129: 113\u2013121","journal-title":"Gastroenterology"},{"key":"BFncpendmet0505_CR57","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1136\/gut.2003.019984","volume":"53","author":"S Dam-Larsen","year":"2004","unstructured":"Dam-Larsen S et al. (2004) Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 53: 750\u2013755","journal-title":"Gut"},{"key":"BFncpendmet0505_CR58","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1053\/j.gastro.2005.05.041","volume":"129","author":"CP Day","year":"2005","unstructured":"Day CP (2005) Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology 129: 375\u2013378","journal-title":"Gastroenterology"},{"key":"BFncpendmet0505_CR59","first-page":"820","volume":"40","author":"E Fassio","year":"2004","unstructured":"Fassio E et al. (2004) Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40: 820\u2013826","journal-title":"Hepatology"},{"key":"BFncpendmet0505_CR60","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S0016-5085(99)70506-8","volume":"116","author":"CA Matteoni","year":"1999","unstructured":"Matteoni CA et al. (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116: 1413\u20131419","journal-title":"Gastroenterology"},{"key":"BFncpendmet0505_CR61","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1053\/jhep.2003.50320","volume":"38","author":"JM Hui","year":"2003","unstructured":"Hui JM et al. (2003) Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 38: 420\u2013427","journal-title":"Hepatology"},{"key":"BFncpendmet0505_CR62","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1053\/jhep.2002.33324","volume":"35","author":"V Ratziu","year":"2002","unstructured":"Ratziu V et al. (2002) Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 35: 1485\u20131493","journal-title":"Hepatology"},{"key":"BFncpendmet0505_CR63","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1096\/fj.01-0396com","volume":"16","author":"G Perlemuter","year":"2002","unstructured":"Perlemuter G et al. (2002) Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 16: 185\u2013194","journal-title":"FASEB J"},{"key":"BFncpendmet0505_CR64","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/hep.510290401","volume":"29","author":"LF Hourigan","year":"1999","unstructured":"Hourigan LF et al. (1999) Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 29: 1215\u20131219","journal-title":"Hepatology"},{"key":"BFncpendmet0505_CR65","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0168-8278(00)00096-9","volume":"34","author":"AD Clouston","year":"2001","unstructured":"Clouston AD et al. (2001) Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. J Hepatol 34: 314\u2013320","journal-title":"J Hepatol"},{"key":"BFncpendmet0505_CR66","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/hep.510250120","volume":"25","author":"S Naveau","year":"1997","unstructured":"Naveau S et al. (1997) Excess weight risk factor for alcoholic liver disease. Hepatology 25: 108\u2013111","journal-title":"Hepatology"},{"key":"BFncpendmet0505_CR67","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1053\/jhep.2002.31782","volume":"35","author":"B Raynard","year":"2002","unstructured":"Raynard B et al. (2002) Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 35: 635\u2013638","journal-title":"Hepatology"},{"key":"BFncpendmet0505_CR68","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1016\/0016-5085(90)91169-7","volume":"99","author":"M Palmer","year":"1990","unstructured":"Palmer M and Schaffner F (1990) Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 99: 1408\u20131413","journal-title":"Gastroenterology"},{"key":"BFncpendmet0505_CR69","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/sj.ijo.0802475","volume":"27","author":"R Padwal","year":"2003","unstructured":"Padwal R et al. (2003) Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 27: 1437\u20131446","journal-title":"Int J Obes Relat Metab Disord"},{"key":"BFncpendmet0505_CR70","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1053\/j.gastro.2006.02.024","volume":"130","author":"P Mathurin","year":"2006","unstructured":"Mathurin P et al. (2006) The evolution of severe steatosis after bariatric surgery is related to insulin resistance. Gastroenterology 130: 1617\u20131624","journal-title":"Gastroenterology"},{"key":"BFncpendmet0505_CR71","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/j.1365-2036.2004.01888.x","volume":"19","author":"A Uygun","year":"2004","unstructured":"Uygun A et al. (2004) Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 19: 537\u2013544","journal-title":"Aliment Pharmacol Ther"},{"key":"BFncpendmet0505_CR72","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/j.1572-0241.2005.41583.x","volume":"100","author":"E Bugianesi","year":"2005","unstructured":"Bugianesi E et al. (2005) A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 100: 1082\u20131090","journal-title":"Am J Gastroenterol"},{"key":"BFncpendmet0505_CR73","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1053\/gast.2002.33666","volume":"122","author":"A Galli","year":"2002","unstructured":"Galli A et al. (2002) Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 122: 1924\u20131940","journal-title":"Gastroenterology"},{"key":"BFncpendmet0505_CR74","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/j.1572-0241.2001.03553.x","volume":"96","author":"SH Caldwell","year":"2001","unstructured":"Caldwell SH et al. (2001) A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 96: 519\u2013525","journal-title":"Am J Gastroenterol"},{"key":"BFncpendmet0505_CR75","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/hep.1840380427","volume":"38","author":"BA Neuschwander-Tetri","year":"2003","unstructured":"Neuschwander-Tetri BA et al. (2003) Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-\u03b3 ligand rosiglitazone. Interim results of a pilot study demonstrating the early effects of the PPAR-\u03b3 ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. Hepatology 38: 1008\u20131017","journal-title":"Hepatology"},{"key":"BFncpendmet0505_CR76","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/hep.20012","volume":"39","author":"K Promrat","year":"2004","unstructured":"Promrat K et al. (2004) A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39: 188\u2013196","journal-title":"Hepatology"},{"key":"BFncpendmet0505_CR77","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa060326","volume":"355","author":"R Belfort","year":"2006","unstructured":"Belfort R et al. (2006) A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355: 2297\u20132307","journal-title":"N Engl J Med"},{"key":"BFncpendmet0505_CR78","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/hep.20092","volume":"39","author":"KD Lindor","year":"2004","unstructured":"Lindor KD et al. (2004) Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39: 770\u2013778","journal-title":"Hepatology"},{"key":"BFncpendmet0505_CR79","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S0022-3476(00)05040-X","volume":"136","author":"JE Lavine","year":"2000","unstructured":"Lavine JE (2000) Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 136: 734\u2013738","journal-title":"J Pediatr"},{"key":"BFncpendmet0505_CR80","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1111\/j.1572-0241.2003.08699.x","volume":"98","author":"SA Harrison","year":"2003","unstructured":"Harrison SA et al. (2003) Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 98: 2485\u20132490","journal-title":"Am J Gastroenterol"},{"key":"BFncpendmet0505_CR81","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S1542-3565(04)00457-4","volume":"2","author":"AJ Sanyal","year":"2004","unstructured":"Sanyal AJ et al. (2004) A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2: 1107\u20131115","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Nature Clinical Practice Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpendmet0505.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpendmet0505","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpendmet0505.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T14:40:14Z","timestamp":1737038414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpendmet0505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":81,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["BFncpendmet0505"],"URL":"https:\/\/doi.org\/10.1038\/ncpendmet0505","relation":{},"ISSN":["1745-8366","1745-8374"],"issn-type":[{"value":"1745-8366","type":"print"},{"value":"1745-8374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}